Good Doctor・Hyperthermic Intraperitoneal Chemotherapy (GDHIPEC) | Versatile Clinical Applications to Meet Diverse Diagnostic and Therapeutic Needs

The multi‑scenario adaptability of the intracavitary hyperthermic perfusion therapy machine is a crucial support for standardized, comprehensive cancer care. As one of the cutting‑edge devices in clinical oncology, the Xi’an Good Doctor Intracavitary Hyperthermic Perfusion Therapy Machine (GDHIPEC) is compatible with preoperative, intraoperative, and postoperative adjuvant therapies, and can be applied across multiple departments for palliative treatment. It covers various body cavities, including the abdominal and thoracic cavities, and is suitable for treating cancers of the gastrointestinal, gynecological, hepatobiliary, urological, and thoracic systems. Moreover, it enables dual‑mode hyperthermic perfusion—both with and without fluid—for tumors involving the pleura and peritoneum, truly achieving full coverage across departments and disease stages with a single device. This helps hospitals establish a standardized system for the prevention and treatment of intracavitary tumors, balancing clinical efficacy, patient benefits, and the practical value of the equipment.

Surgical hyperthermic perfusion therapy Medical hyperthermic perfusion therapy

01 Hyperthermic Perfusion “Pre‑treatment” Prior to Cytoreductive Surgery (CRS)

For patients with locally advanced tumors in the thoracic or abdominal cavities—characterized by poorly defined tumor margins or widespread micrometastases—GDHIPEC enables neoadjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) prior to CRS, delivering a preoperative “downstaging and tumor reduction” effect while effectively eradicating micrometastases. By precisely circulating a chemotherapy‑laden perfusate at a constant temperature of 42.5°C within the body cavity for 60 minutes, the synergistic interplay between hyperthermia and chemotherapeutic agents reduces tumor volume, lowers tumor staging (as measured by the Peritoneal Cancer Index, PCI, or the Pleural Tumor Index, PTI), and loosens adhesions between the tumor and surrounding tissues. This creates more favorable conditions for subsequent cytoreductive surgery (CRS)—an approach aligned with the “conversion strategy” outlined in the CACA Guidelines. Moreover, preoperative perfusion can promptly eliminate free cancer cells and microscopic foci within the body cavity, thereby minimizing the risk of intraoperative dissemination and interrupting tumor metastatic pathways from the very outset, ultimately enhancing the completeness of treatment.

Preoperative hyperthermic perfusion therapy
 

02 Intraoperative and postoperative “thermal ablation to control metastasis” in CRS

During cytoreductive surgery for tumors on the pleural or peritoneal surfaces, residual free cancer cells and microscopic tumor nodules represent critical risk factors that can lead to postoperative recurrence and metastasis. GDHIPEC leverages a core advantage: continuous, constant‑temperature, constant‑pressure hyperthermic perfusion administered over one hour. Following completion of tumor resection—known as cytoreductive surgery (CRS)—it delivers hyperthermic perfusion therapy or chemotherapy concurrently, or initiates hyperthermic chemotherapy within one week after surgery, in accordance with the “treatment paradigm” outlined in the CACA Guidelines issued by the Chinese Anti‑Cancer Association. By circulating a large volume of chemotherapeutic agent at a high flow rate at a constant temperature of 42.5°C within the surgical cavity, the treatment harnesses the mechanical scouring action of the high‑velocity fluid to perform a thorough “thermal cleaning” of the body cavity, effectively eliminating free cancer cells and microscopic tumor nodules that are invisible to the naked eye. Simultaneously, the synergistic effects of hyperthermia and chemotherapy directly disrupt the structural integrity of residual cancer cells, blocking at the source the pathways through which tumor cells may implant and metastasize. This approach safeguards surgical outcomes, significantly reducing the risk of postoperative recurrence and extending both disease‑free survival and overall survival.

Intraoperative thermal perfusion during surgery

Postoperative hyperthermic perfusion in surgery
 

03 Hyperthermic Intraperitoneal Chemotherapy for Recurrence Prevention After Radical Tumor Resection

Following radical surgery for thoracic, gastrointestinal, and gynecologic malignancies, there remains a risk of subclinical metastasis—manifested as free cancer cell seeding on serosal surfaces and residual disease. This risk is particularly pronounced in high‑risk patients with serosal invasion or lymph node metastases. Intraoperative and postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) represents an important strategy for preventing recurrence, aligning with the “preventive approach” advocated in the Chinese Anti‑Cancer Association’s CACA Guidelines. After surgery, using indwelling catheters, HIPEC can be administered without the need for additional anesthesia, employing constant‑temperature circulating hyperthermic perfusion. Under the synergistic effects of heat, the locally delivered high‑concentration chemotherapeutic agent penetrates the peritoneum and interstitial spaces, effectively eradicating any free cancer cells that may have been dislodged during the procedure. At the same time, this approach reduces postoperative adhesions, lowers the incidence of local tumor recurrence and related complications, strengthens the foundation for patients’ postoperative recovery, and significantly prolongs disease‑free survival.

First hyperthermic perfusion two weeks postoperatively in surgical patients.
 

04 “Artificial Pleural and Peritoneal Effusions” for Hyperthermic Intraperitoneal Chemotherapy

For certain cancer patients without cavity‑related effusions, conventional hyperthermic intracavitary perfusion is difficult to implement due to the lack of an effective delivery vehicle and the risk of organ injury. GDHIPEC has broken new ground by overcoming these limitations: it pioneered ultrasound‑guided percutaneous catheter placement, unidirectional perfusion, and a “synthetic pleural/abdominal fluid” technique, creating a standardized hyperthermic perfusion environment specifically for patients without effusions. By generating this artificial fluid, the treatment precisely controls and maintains a constant‑temperature, circulating perfusion within the body cavity, allowing the chemotherapy‑laden perfusate to circulate continuously at a therapeutic temperature of 42.5°C. Even in the absence of cavity effusions, this approach delivers a dual effect—high local drug concentrations combined with thermal therapy—enabling precise targeting and elimination of latent free cancer cells and microscopic metastases within the cavity. This effectively fills a critical gap in conventional therapies, opening a new avenue for localized, precision treatment in patients without cavity‑related effusions.

Artificial “ascites” hyperthermic perfusion
 

05 Internal Medicine Treats Ascites and Prevents “Reaccumulation”

Malignant pleural and peritoneal effusions are common complications of advanced cancer. Recurrent, poorly controlled effusions can cause symptoms such as chest tightness, abdominal distension, and dyspnea, leading to a rapid decline in quality of life. GDHIPEC offers a “both symptomatic and root‑cause” approach to malignant effusions: on the one hand, it employs high‑volume, unidirectional infusion and lavage, using warmed saline to replace the malignant fluid, thereby thoroughly eliminating the tumor‑cell microenvironment; at the same time, the synergistic effects of hyperthermia and chemotherapeutic agents directly eradicate metastatic lesions on the pleura and peritoneum, blocking effusion formation at its source. On the other hand, the thermal effect helps repair the cavity lining, improving the exudative milieu and enabling the serosal surface to form a protective barrier that prevents the leakage of albumin and other nutrients. Compared with conventional methods—repeated paracentesis or drainage followed by drug administration—that address only the symptoms without tackling the underlying problem—GDHIPEC effectively controls recurrence, prevents effusion reaccumulation, rapidly alleviates patient discomfort, markedly improves quality of life, and creates favorable conditions for subsequent multimodal therapies.

Intraperitoneal hyperthermic perfusion Intrathoracic hyperthermic perfusion
 

06 Multi-chamber drainage for fluid accumulation, combined with localized hyperthermic chemotherapy, with minimal toxic side effects.

GDHIPEC overcomes the limitations of single‑cavity treatment, enabling therapy across multiple body cavities—including the abdominal and thoracic spaces—and providing comprehensive management of effusions and metastases arising from tumors in different anatomical sites. Whether it is malignant pleural effusion caused by lung cancer, esophageal cancer, thymoma, or malignant pleural mesothelioma; intra‑abdominal fluid accumulation due to gastrointestinal or ovarian cancers; or even non‑muscle‑invasive bladder cancer, GDHIPEC can be precisely tailored to each clinical scenario. The treatment regimen centers on local hyperthermia combined with chemotherapy, leveraging the “serosa–plasma barrier” effect to achieve intracavitary drug concentrations 20 to 1,000 times higher than systemic levels. This not only enhances anti‑tumor efficacy but also significantly reduces systemic drug exposure, thereby markedly diminishing the systemic adverse effects associated with conventional chemotherapy. With its precise temperature control—maintaining an intracavitary temperature of 42.5°C—GDHIPEC ensures potent cytotoxicity against cancer cells while sparing normal tissues, resulting in far lower toxicity compared to systemic chemotherapy. Consequently, even elderly or frail patients can tolerate the therapy, achieving the dual goals of high efficacy and low toxicity.

Minimally invasive percutaneous catheterization causes minimal tissue damage. Chemotherapy drugs are administered via hyperthermic perfusion.
 

07 Multi-department, multi-team collaborative care to prolong life

The Good Doctor hyperthermic perfusion technique breaks down departmental barriers, enabling collaboration across surgery, medical oncology, gynecology, gastroenterology, interventional radiology, and other specialties, and integrating into multidisciplinary tumor boards (MDTs) and multidisciplinary treatment systems. For tumors at different stages and of various types, it can flexibly combine surgical resection, intravenous chemotherapy, targeted therapy, immunotherapy, and other modalities: early-stage patients can achieve radical enhancement and recurrence prevention through “surgery plus intraoperative hyperthermic perfusion”; mid-stage patients can undergo “postoperative hyperthermic perfusion plus systemic chemotherapy” to consolidate therapeutic effects and prolong survival; while advanced-stage patients benefit from a palliative regimen of “hyperthermic perfusion plus targeted/immunotherapy” to control the disease, alleviate symptoms, and improve quality of life. Through multidisciplinary, multi‑team collaboration, this approach maximizes the advantage of hyperthermic perfusion in achieving “localized, precise tumor clearance,” comprehensively enhancing overall cancer care, effectively extending patients’ survival, and offering long-term survival prospects to patients at different stages of the disease.

From preoperative preparation that lays a solid foundation for treatment, to intraoperative thermal ablation that eliminates the risk of metastasis, to postoperative consolidation that reduces the likelihood of recurrence; from groundbreaking innovations in managing patients without fluid accumulation, to comprehensive management of multi‑cavity effusions, to multidisciplinary collaboration that empowers care across the entire disease trajectory—GDHIPEC, with its core strengths in precise temperature control, constant temperature and pressure, synergistic thermochemotherapy, and mechanical flushing, transcends the limitations of conventional therapies, spanning all clinical scenarios and stages of cancer care.

GDHIPEC not only provides core support for hospitals in establishing a standardized system for the prevention and treatment of body‑cavity tumors, but also, with its hallmarks of “high efficacy, low toxicity, and precise customization,” tailors individualized local treatment plans to patients across different stages and tumor types. This approach both enhances clinical diagnostic and therapeutic efficiency and substantially improves patients’ quality of life while extending survival, using cutting-edge technology to rekindle hope for cancer patients and underscoring the core value of medical science in empowering clinical practice and safeguarding human life.